SCHEMBL21450985

SCHEMBL21450985

N#Cc1ccc2sc3c(Cl)nc4ccccc4c3c(=O)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 1/20 0.44
TOP2A P11388 1/20 0.44
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
G6PD P11413 2/20 0.40
KDM4E B2RXH2 2/20 0.40
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
ATM Q13315 1/20 0.36
MIF P14174 1/20 0.36
KDM1A O60341 1/20 0.35
PRSS12 P56730 1/20 0.35
ADORA2A P29274 1/20 0.34
STS P08842 1/20 0.34
EGLN1 Q9GZT9 1/20 0.34
PSMB8 P28062 1/20 0.34
PPARA Q07869 1/20 0.34
NPC1 O15118 1/20 0.34
HCRTR1 O43613 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17655673 0.84 KDM4E (0.58) TOP1TOP2AKDM4EKMT2AMEN1
SCHEMBL21450906 0.82 TOP1 (0.43) TOP1TOP2AG6PDKDM4EKMT2A
SCHEMBL21450975 0.82 ALDH1A1 (0.46) TOP1TOP2AKDM4EKMT2AMEN1
SCHEMBL21451080 0.79 NPC1 (0.43) TOP1TOP2AKDM4EKMT2AEGLN1
SCHEMBL21451040 0.79 TOP1 (0.41) TOP1TOP2AKDM4EKMT2AMEN1
SCHEMBL21451018 0.79 TOP1 (0.41) TOP1TOP2AG6PDKDM4EMIF
SCHEMBL21450818 0.79 KDM4E (0.59) TOP1TOP2AKDM4EKMT2AMEN1
SCHEMBL16339008 0.77 TOP1 (0.64) TOP1TOP2AKDM4ENPC1MAPT
SCHEMBL21450825 0.76 TOP1 (0.48) TOP1TOP2AKDM4EKMT2AMEN1
SCHEMBL21451124 0.76 MAPT (0.43) TOP1TOP2AKDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
WO-2019191896-A1 FMS-LIKE TYROSINE KINASE INHIBITORS 3SM BIOTRON INC. (CN) 2019-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332476-B2 Fms-like tyrosine kinase inhibitors FLT3, FLT4, FLT1 TOP1 2980/4885TOP2A 2701/4885CA1 3978/4885
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS FLT3, FLT4, FLT1 TOP1 2980/4885TOP2A 2701/4885CA1 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.